GrowingWithAK

Mirae Asset Healthcare Fund - Regular Plan - Growth

Equity · Sectoral/ Thematic · Regular · Growth

Regular TER: 2.04% · as of

2021-10-25 → 2026-10-21

min ₹19.50 change +89.3% max ₹46.67

₹43.0780

as of 2026-10-21 · -0.59% vs 2026-10-19

2018-07-03

AMFI archive begins Apr 2006

-20.09%

trough 2020-03-23 (since archive start)

Window Scheme CAGR Benchmark CAGR Excess Period
1y +9.89% — — 2025-10-23 → today · 1.0y
3y +19.86% — — 2023-10-23 → today · 3.0y
5y +13.60% — — 2021-10-22 → today · 5.0y

Benchmark assignment is mapped by category and sub-category from public sources. "Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).

Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.

0% -12.4% to -10.1%: 41 windows -10.1% to -7.9%: 68 windows -7.9% to -5.6%: 66 windows -5.6% to -3.3%: 60 windows -3.3% to -1.0%: 40 windows -1.0% to +1.3%: 60 windows +1.3% to +3.6%: 44 windows +3.6% to +5.9%: 29 windows +5.9% to +8.2%: 17 windows +8.2% to +10.5%: 33 windows +10.5% to +12.8%: 58 windows +12.8% to +15.1%: 102 windows +15.1% to +17.4%: 100 windows +17.4% to +19.7%: 90 windows +19.7% to +22.0%: 55 windows +22.0% to +24.3%: 36 windows +24.3% to +26.6%: 32 windows +26.6% to +28.9%: 16 windows +28.9% to +31.2%: 4 windows +31.2% to +33.5%: 11 windows +33.5% to +35.8%: 18 windows +35.8% to +38.1%: 24 windows +38.1% to +40.4%: 25 windows +40.4% to +42.6%: 22 windows +42.6% to +44.9%: 26 windows +44.9% to +47.2%: 27 windows +47.2% to +49.5%: 36 windows +49.5% to +51.8%: 25 windows +51.8% to +54.1%: 42 windows +54.1% to +56.4%: 22 windows -12% +56%

Median 1y return

+14.9%

Mean 1y return

+16.4%

Best / worst 1y

+56.4% / -12.4%

Windows positive

75%

5th %ile -9.3%
25th %ile +0.0%
75th %ile +25.9%
95th %ile +51.9%

Same idea over longer holding periods. Returns are CAGR (annualised) so they're directly comparable to the trailing-CAGR table above.

Period Median Mean Worst Best % positive Windows
3y rolling +21.4% +21.9% +12.5% +33.3% 100% 1306
5y rolling +21.3% +21.1% +12.9% +32.0% 100% 813

Of all the rolling windows we observed, how often did this fund's return exceed the benchmark's over the same window. A higher fraction means more consistent outperformance, but says nothing about future windows.

Period Windows beat Total windows % beat Avg excess
(annualised)
1y rolling 349 590 59% +0.9%
3y rolling 99 99 100% +1.5%

How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.

Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year
2026 -4.7 +7.8 -3.6 +6.2 +4.1 +4.3 +4.5 +2.0 -3.1 -4.3 · · +12.8
2025 -7.9 -8.0 +9.0 +0.5 +0.6 +3.4 +4.3 -4.2 -1.0 +2.6 +0.0 -1.4 -3.4
2024 +6.0 +2.5 +0.9 +0.2 -0.8 +5.1 +11.0 +7.2 +0.8 -1.3 -1.5 +4.1 +39.1
2023 -1.7 -4.5 +1.1 +5.0 +1.2 +9.0 +7.8 +1.3 +2.6 -4.7 +10.4 +3.5 +34.0
2022 -6.9 -4.3 +4.5 -1.3 -5.8 -3.6 +7.0 +0.4 +1.6 +1.2 -0.1 -4.2 -11.8
2021 -5.6 +1.4 +3.1 +9.1 +4.3 +5.0 +3.7 +2.5 -0.5 -4.2 +2.4 +3.4 +26.6
2020 +4.8 -0.1 -7.4 +26.1 +2.5 +2.2 +13.3 +0.3 +9.1 -2.0 +4.1 +7.2 +73.9
2019 +0.7 -1.3 +4.4 +0.7 -5.3 -1.6 -0.8 +3.1 -1.4 +5.4 +2.9 -0.1 +6.4
2018 · · · · · · · +8.4 -3.2 -0.5 -1.2 -2.1 +1.1
Avg -1.9 -0.8 +1.5 +5.8 +0.1 +3.0 +6.4 +2.3 +0.6 -0.4 +2.1 +1.3 +23.5

All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row. The Avg row is the plain average of each column across the years shown (7 complete calendar years in the last column); the running month is left out of it.

Equity 96.6%
ETF / FoF 0.0%
Other / unclassified 3.4%
Equity split: Large 35.0% Mid 42.1% Small 19.5%

Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).

  • Large Cap 35.0%
  • Mid Cap 42.1%
  • Small Cap 19.5%
  • ETF / FoF (incl. gold/silver) 0.0%
  • Unlisted & other equity 3.4%
· vs · share of this fund's AUM that sits in stocks the index also includes

No holdings data yet for this fund.

Stock Sector % of fund
Sun Pharmaceutical Industries Ltd. Pharmaceuticals & Biotechnology 10.15%
Divi's Laboratories Ltd. Pharmaceuticals & Biotechnology 9.79%
Torrent Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology 6.80%
Apollo Hospitals Enterprise Ltd. Healthcare Services 5.62%
Laurus Labs Ltd. Pharmaceuticals & Biotechnology 5.51%
Dr. Reddy's Laboratories Ltd. Pharmaceuticals & Biotechnology 4.84%
Glenmark Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology 4.78%
Aurobindo Pharma Ltd. Pharmaceuticals & Biotechnology 3.78%
Alkem Laboratories Ltd. Pharmaceuticals & Biotechnology 3.76%
IPCA Laboratories Ltd. Pharmaceuticals & Biotechnology 3.39%
Krishna Institute of Medical Sciences Ltd. Healthcare Services 3.39%
Aster DM Quality Care Ltd. Healthcare Services 3.33%
Sai Life Sciences Ltd. Pharmaceuticals & Biotechnology 3.23%
Onesource Specialty Pharma Ltd. Pharmaceuticals & Biotechnology 3.01%
Fortis Healthcare Ltd. Healthcare Services 2.94%
Dr. Lal Path labs Ltd. Healthcare Services 2.90%
Gland Pharma Ltd. Pharmaceuticals & Biotechnology 2.69%
Cipla Ltd. Pharmaceuticals & Biotechnology 2.63%
Eris Lifesciences Ltd. Pharmaceuticals & Biotechnology 2.39%
Max Healthcare Institute Ltd. Healthcare Services 2.35%
Healthcare: 98.1% Chemicals: 1.9% ETF / FoF: 0.0%
  • Healthcare 98.1%
  • Chemicals 1.9%
  • ETF / FoF 0.0%

Sharpe

+0.96

excess return per unit of total volatility

Sortino

+1.34

excess return per unit of downside vol

Calmar

+1.23

CAGR / |max DD| in window

Beta vs benchmark

+0.91

scheme sensitivity to benchmark moves

Tracking error

+4.60%

annualised stdev of (scheme − benchmark)

Up capture

+92.3%

% of benchmark gain captured on up days

Down capture

+88.7%

% of benchmark loss participated in

Risk-free rate assumed 6.0% annualised. Benchmark = Nifty Healthcare Index (assigned by category mapping).

Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.